HANSOH PHARMA (03692): Two New Indications for Innovative Drug Ameile® Successfully Included in 2025 National Reimbursement Drug List

Stock News12-08 07:08

HANSOH PHARMA (03692) announced that two new indications for its innovative drug Ameile® have been successfully included in the updated National Reimbursement Drug List (NRDL) for 2025, covering basic medical insurance, work-related injury insurance, and maternity insurance. Additionally, all indications for Shengluolai® and Hengmu® have been renewed in the 2025 NRDL. The updated list will take effect on January 1, 2026.

1. **Ameitinib Mesylate Tablets (Brand Name: Ameile®)** – The two newly approved indications in March and April 2025 have been added to the 2025 NRDL: - Treatment of adult patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations who have undergone surgical resection. - Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations who have not experienced disease progression during or after platinum-based chemoradiotherapy.

2. **Peginesatide Injection (Brand Name: Shengluolai®)** – Both indications have been renewed in the 2025 NRDL: - Treatment of anemia caused by chronic kidney disease, including: a. Adult non-dialysis patients not previously treated with erythropoiesis-stimulating agents (ESA). b. Adult dialysis patients currently receiving short-acting erythropoietin therapy.

3. **Tenofovir Alafenamide Tablets (Brand Name: Hengmu®)** – Renewed in the 2025 NRDL for the treatment of chronic hepatitis B in adult patients.

Furthermore, several other innovative drugs from the group remain within the NRDL agreement period, valid until December 31, 2026: - Flumatinib Mesylate Tablets (Brand Name: Haosen Xinfu®) - PEG-Loxenatide Injection (Brand Name: Fulaimi®) - Inebilizumab Injection (Brand Name: Xinyue®) for NMOSD - Ameitinib Mesylate Tablets (Brand Name: Ameile®) for first- and second-line NSCLC treatment

Additionally, Morinidazole Sodium Chloride Injection (Brand Name: Mailinda®) has been included in the NRDL Class B category.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment